Foresite Capital

Foresite Capital company information, Employees & Contact Information

Explore related pages

Related company profiles:

Foresite Capital is a multi-stage healthcare and life sciences investment firm with ~ $3.5B in assets under management (as of 06/30/24). The firm aims to address areas of great unmet need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Foresite Capital uses a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare, including 10x Genomics, Relay Therapeutics, Element Biosciences, Inscripta, as well as companies developing next generation therapeutics. Founded in 2011, Foresite Capital is based in San Francisco.

Company Details

Employees
57
Founded
-
Address
900 Larkspur Landing Circle,
Phone
415-877-4887
Email
in****@****tal.com
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Keywords
Boston.
HQ
Larkspur, California
Looking for a particular Foresite Capital employee's phone or email?

Foresite Capital Questions

News

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs Bain Capital

RayThera Raises $110 Million in Series A Financing - Yahoo Finance

RayThera Raises $110 Million in Series A Financing Yahoo Finance

Sollis Health Completes $33 Million Series B Funding Round Led by Foresite Capital to Support Growing Demand for Personalized, High-Touch Healthcare - PR Newswire

Sollis Health Completes $33 Million Series B Funding Round Led by Foresite Capital to Support Growing Demand for Personalized, High-Touch Healthcare PR Newswire

RayThera Raises $110 Million in Series A Financing - The AI Journal

RayThera Raises $110 Million in Series A Financing The AI Journal

Foresite Capital Raises $900M to Invest in Healthcare and Life Science Startups at All Stages - Business Wire

Foresite Capital Raises $900M to Invest in Healthcare and Life Science Startups at All Stages Business Wire

VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology - MedCity News

VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology MedCity News

Supported by leading investors - Evonetix

Supported by leading investors Evonetix

Foresite Capital raises $900M sixth fund for investing in life sciences companies - TechCrunch

Foresite Capital raises $900M sixth fund for investing in life sciences companies TechCrunch

Foresite Capital Closes $900 Million Life Sciences Venture Fund - The Wall Street Journal

Foresite Capital Closes $900 Million Life Sciences Venture Fund The Wall Street Journal

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction - Yahoo Finance

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction Yahoo Finance

Foresite Capital Strengthens Investor Relations and Business Development Teams with Addition of Hadi Tabbaa as Managing Director - Business Wire

Foresite Capital Strengthens Investor Relations and Business Development Teams with Addition of Hadi Tabbaa as Managing Director Business Wire

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform - PR Newswire

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform PR Newswire

Foresite Capital Raises $173 Million to Fund Foresite Labs Incubated Life Science Companies - Business Wire

Foresite Capital Raises $173 Million to Fund Foresite Labs Incubated Life Science Companies Business Wire

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors - PR Newswire

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors PR Newswire

Alisa Mall Named As Managing Director at Foresite Capital - Business Wire

Alisa Mall Named As Managing Director at Foresite Capital Business Wire

Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing - PR Newswire

Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing PR Newswire

XinThera Closes $50M Series B Financing - Business Wire

XinThera Closes $50M Series B Financing Business Wire

SutroVax Announces $85M Series C Financing led by TPG Growth - PR Newswire

SutroVax Announces $85M Series C Financing led by TPG Growth PR Newswire

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences - Business Wire

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences Business Wire

Cullinan Oncology Completes $131.2 Million Series C Financing - Business Wire

Cullinan Oncology Completes $131.2 Million Series C Financing Business Wire

Top Foresite Capital Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant